Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

December 16, 2014

CAMBRIDGE, Mass.Dec.

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

December 12, 2014

 CAMBRIDGE, Mass.--()--Acceleron Pharma Inc.

Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers

Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers

December 11, 2014

- Papers in Cell and Cancer Cell describe in vivo activity of CDK7 inhibitors; further validate company’s lead preclinical program -

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today the recent publication of two studies that further demonstrate the critical role of CDK7 in cancers driven by oncogenic transcription factors, including certain lung and pediatric cancers.

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences

December 11, 2014

- Posters at 56th ASH Annual Meeting and 2014 San Antonio Breast Cancer Symposium highlight identification of patient subtypes and novel drug targets in acute myeloid leukemia and breast cancer -

Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee

Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee

December 10, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors

Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors

December 10, 2014

CAMBRIDGE, Mass.Dec.

Symbiota Appoints International Plant Sciences Leader Dr. Roger Beachy to its Board of Directors

Symbiota Appoints International Plant Sciences Leader Dr. Roger Beachy to its Board of Directors

December 10, 2014

CAMBRIDGE, Mass., December 10, 2014 /PRNewswire/ — Symbiota™, pioneer of plant microbiome solutions that naturally promote plant health and improve agricultural production, today announced the key addition of Dr. Roger Beachy to its board of directors.

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

December 9, 2014

DUBLIN & LEXINGTON, Mass.--()--Jazz

New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition

New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition

December 8, 2014

Luspatercept and sotatercept increased hemoglobin levels and achieved transfusion independence in patients with lower risk myelodysplastic syndromes

Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency

Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency

December 8, 2014

 AG-348 Achieved Proof-of-Mechanism Through Substantial Effects on Two Key Biomarkers of Pyruvate Kinase Activity and Pathway Activation

Data Presented at ASH Support Initiation of a Phase 2 Trial in Patients with

PK Deficiency in First Half 2015